title: Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus.
abstract: Downbeat nystagmus (DBN) is a common, usually persistent ocular motor sign in vestibulocerebellar midline lesions. Postural imbalance in DBN may increase on lateral gaze when downbeat nystagmus increases. 3,4-Diaminopyridine (3,4-DAP) has been shown to suppress the slow-phase velocity component of downbeat nystagmus and its gravity-dependent component with concomitant improvement of oscillopsia. Because the pharmacological effect is thought to be caused by improvement of the vestibulocerebellar Purkinje cell activity, the effect of 3,4-DAP on the postural control of patients with downbeat nystagmus syndrome was examined. Eye movements were recorded with the video-based Eyelink II system. Postural sway and pathway were assessed by posturography in lateral gaze in the light and on eye closure. Two out of four patients showed an improvement of the area of postural sway by 57% of control (baseline) on eye closure. In contrast, downbeat nystagmus in gaze straight ahead and on lateral gaze did not benefit in these two patients, implying a specific influence of 3,4-DAP on the vestibulocerebellar control of posture. It was concluded that 3,4-DAP may particularly influence the postural performance in patients with downbeat nystagmus.
authors.affiliation: Department of Neurology, University of Lübeck, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Sprenger
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Zils
authors.forename: Holger
authors.initials: H
authors.lastname: Rambold
authors.forename: Thurid
authors.initials: T
authors.lastname: Sander
authors.forename: Christoph
authors.initials: C
authors.lastname: Helmchen
mesh_terms: D015761:4-Aminopyridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000369:Aged, 80 and over; D000077770:Amifampridine; D002531:Cerebellum / Q000473:pathology / Q000503:physiopathology; D005133:Eye Movements / Q000187:drug effects / Q000502:physiology; D005260:Female; D005403:Fixation, Ocular / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008875:Middle Aged; D009759:Nystagmus, Pathologic / Q000188:drug therapy* / Q000503:physiopathology*; D011187:Posture / Q000502:physiology*; D026902:Potassium Channel Blockers / Q000627:therapeutic use*; D012027:Reflex, Vestibulo-Ocular / Q000187:drug effects / Q000502:physiology
chemical_list: D026902:Potassium Channel Blockers; D015761:4-Aminopyridine; D000077770:Amifampridine